Evidence map›Paper›PMID 40723216›Full record

ArticleCancers2025

Blood-Epigenetic Biomarker Associations with Tumor Immunophenotype in Patients with Urothelial Carcinoma from JAVELIN Bladder 100.

Thomas Powles, Srikala S Sridhar, Joaquim Bellmunt, Cora N Sternberg, Petros Grivas, Ewan Hunter, Matthew Salter, Ryan Powell, Ann Dring, Jayne Green and 13 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02603432 (A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02603432 phase3completednot on this map

A phase 3, multicenter, multinational, randomized, open-label, parallel-arm study of avelumab (msb0010718c) plus best supportive care versus best supportive care alone as a maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line platinum-containing chemotherapy

TypeinterventionalSponsorPfizerRan2016 to 2023Enrolled700ConditionsUrothelial CancerArmsAvelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Paradigm Lost.Cancers · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Thomas PowlesBarts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, Charterhouse Square, London EC1M 6BQ, UK.
Srikala S SridharPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.ORCID 0000-0002-6994-1285
Joaquim BellmuntDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Cora N SternbergEnglander Institute for Precision Medicine, Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0003-3938-2627
Petros GrivasFred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA.ORCID 0000-0003-3965-3394
Ewan HunterOxford BioDynamics Plc, Oxford OX4 2WB, UK.
Matthew SalterOxford BioDynamics Plc, Oxford OX4 2WB, UK.
Ryan PowellOxford BioDynamics Plc, Oxford OX4 2WB, UK.
Ann DringOxford BioDynamics Plc, Oxford OX4 2WB, UK.
Jayne GreenOxford BioDynamics Plc, Oxford OX4 2WB, UK.
Alexandre AkoulitchevOxford BioDynamics Plc, Oxford OX4 2WB, UK.
Roy RonenData4Cure, Inc., Waltham, MA 02451, USA.
Janusz DutkowskiData4Cure, Inc., Waltham, MA 02451, USA.
Robert AmezquitaPfizer, San Diego, CA 92121, USA.
Chao-Hui HuangPfizer, San Diego, CA 92121, USA.
Diane FernandezPfizer, San Diego, CA 92121, USA.ORCID 0000-0003-1365-5172
Robbin NamekiPfizer, San Diego, CA 92121, USA.
Keith A ChingPfizer, San Diego, CA 92121, USA.
Jie PuPfizer, Tucson, AZ 85714, USA.
Michelle SaulPfizer, Tucson, AZ 85714, USA.
Shibing DengPfizer, San Diego, CA 92121, USA.
Alessandra di PietroPfizer srl, 20152 Milano, Italy.
Craig B DavisPfizer, San Diego, CA 92121, USA.

Funding

Merck (CrossRef Funder ID: 10.13039/100009945) and was previously conducted under an alliance between Merck and Pfizer. N/A
6 · The paper itself

Abstract

BACKGROUND/

objectivesResponse to immune checkpoint inhibitors (ICIs) is associated with several biological pathways, including tumor immunogenicity and antitumor immunity. Identifying host factors involved in these pathways may guide personalized ICI treatment.

methodsWe describe the application of chromatin conformation assays to blood from patients with advanced urothelial carcinoma from the phase 3 JAVELIN Bladder 100 trial (NCT02603432). This trial demonstrated a significant survival benefit with avelumab maintenance plus best supportive care (BSC) vs. BSC alone following non-progression with platinum-based chemotherapy as first-line therapy. Blood-based chromatin conformation markers (CCMs) were screened for associations with high/low immune effector gene expression in tumors and for interactions with outcomes and tumor mutation burden.

resultsCandidate CCMs included genes involved in several immune response pathways, such as

conclusionsOur findings suggest that polygenic host factors may affect response to ICIs and support further investigation of chromatin conformation assays.

Indexed as

avelumabchromatin conformationepigeneticsimmune checkpoint inhibitorsspatial transcriptomicsurothelial carcinoma

Identifiers

PMID40723216
PMCPMC12293378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.